Adjuvance Technologies

United States
Fennville, Michigan, United States

Company profile

Adjuvance Technologies company profile

Adjuvance is a privately held biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. Adjuvants are critical components that are added to many vaccines to improve the immune response.

Business identity

Phone number
4028175050
Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2009-07-08

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$20M
Last funding
Series A / $20M / 2020-01-29
Last equity funding
Series A / $20M
Investors
2
Lead investors
2
Founders
1
Articles
15

Founders and investors

Founders

Jeffrey Gardner

Lead investors

MorningsideNebraska Angel Network

Investors

MorningsideNebraska Angel Network